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Migration of the Swine Influenza Virus ␦-Cluster Hemagglutinin NLinked Glycosylation Site from N142 to N144 Results in Loss of
Antibody Cross-Reactivity
Ben M. Hause,a,b Douglas L. Stine,a Zizhang Sheng,c Zhao Wang,b,d Suvobrata Chakravarty,c Randy R. Simonson,a and Feng Lib,d
Newport Laboratories, Worthington, Minnesota, USA,a and Department of Veterinary and Biomedical Sciences,b Department of Chemistry and Biochemistry,c and
Department of Biology and Microbiology,d South Dakota State University, Brookings, South Dakota, USA

Routine antigenic characterization of swine influenza virus isolates in a high-throughput serum neutralization (HTSN)
assay found that approximately 20% of isolates were not neutralized by a panel of reference antisera. Genetic analysis revealed that nearly all of the neutralization-resistant isolates possessed a seasonal human-lineage hemagglutinin (HA; ␦
cluster). Subsequent sequencing analysis of full-length HA identified a conserved N144 residue present only in neutralization-resistant strains. N144 lies in a predicted N-linked glycosylation consensus sequence, i.e., N-X-S/T (where X is any
amino acid except for proline). Interestingly, neutralization-sensitive viruses all had predicted N-linked glycosylation sites
at N137 or N142, with threonine (T) occupying position 144 of HA. Consistent with the HTSN assay, hemagglutination
inhibition (HI) and serum neutralization (SN) assays demonstrated that migration of the potential N-linked glycosylation
site from N137 or N142 to N144 resulted in a >8-fold decrease in titers. These results were further confirmed in a reverse
genetics system where syngeneic viruses varying only by predicted N-glycosylation sites at either N142 or N144 exhibited
distinct antigenic characteristics like those observed in field isolates. Molecular modeling of the hemagglutinin protein
containing N142 or N144 in complex with a neutralizing antibody suggested that N144-induced potential glycosylation
may sterically hinder access of antibodies to the hemagglutinin head domain, allowing viruses to escape neutralization.
Since N-linked glycosylation at these sites has been implicated in genetic and antigenic evolution of human influenza A
viruses, we conclude that the relocation of the hemagglutinin N-linked glycosylation site from N142 to N144 renders swine
influenza virus ␦-cluster viruses resistant to antibody-mediated neutralization.

I

nfluenza viruses possess a number of mechanisms to elude host
humoral immunity against hemagglutinin (HA), which mediates viral entry. Reassortment of genome segments can lead to
antigenic shift, while gradual accumulation of mutations leads to
genetic drift (10, 21). In addition to mutations in the antigenic
epitopes of HA that can impact the ability of preexisting antibodies to recognize mutant HA, mutations in N-linked glycosylation
of HA can promote viral evasion of antibody recognition by altering the oligosaccharide layer surrounding HA (22). Glycan residues can restrict the binding of some antibodies to their epitopes,
leading to loss of antibody recognition and immunogenicity in a
phenomenon known as glycan shielding (30, 31). Additionally,
mutation and genetic drift occur preferentially at positions in the
HA globular head that are not protected by glycans (9). Glycan
residues also influence receptor binding and consequently can
affect viral replication kinetics.
The evolution of influenza viruses frequently includes modification of the number and position of glycosylation sites (18). For
H3N2 viruses, the number of glycosylation sites has increased
from 2 to 10 over the last 40 years (4). However, increasingly
glycosylated HA has been correlated with decreased virulence in
mice and reduced viral fitness (8, 27). While increasing glycosylation can shield HA from neutralizing antibodies, the viral affinity
for cellular receptors is obligatorily decreased (1, 8). Also, compensatory mutations in either the HA or neuraminidase (NA) are
required to balance receptor binding and release activities (29).
These compensatory mutations in NA have been associated with
the acquisition of natural resistance to NA inhibitors (14).
Numerous lineages of swine influenza virus circulate concur-
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rently in pigs, including ␤-, ␥-, and ␦-cluster H1N1 and H1N2
viruses, as well as the H3N2 subtype (19). The ␦ cluster was originally subdivided into two subclusters (␦-I and ␦-II), but more
recent work demonstrated five distinct genetic subclusters (␦-A,
␦-B, ␦-C, ␦-D, and ␦-E) representing at least three antigenically
distinct groups (11, 28). In our laboratory, routine antigenic characterization of swine influenza viruses isolated from pigs displaying influenza-like illness found that approximately 20% of field
isolates in 2011 were not neutralized by a panel of antisera (H1
clusters ␣, ␤, ␥, ␦-A, ␦-B, ␦-C, ␦-D, and ␦-E, 2009 pandemic H1N1
virus, and H3 clusters I, III, and IV) representing circulating subtypes and clusters of influenza virus in North America. Genetic
analysis found that nearly all of the nonneutralized viruses were
located in the ␦ cluster. Interestingly, the HA genes of the nonneutralized viruses were nearly identical to those of others that were
neutralized by reference antisera. The aim of this study was to
determine the molecular basis for the apparent variability observed in ␦-cluster antigenic characterization to allow for more
effective vaccine formulations.
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MATERIALS AND METHODS
Cells and viruses. Clinical samples (nasal swabs or lung tissue) were collected from pigs exhibiting influenza-like illness and were submitted to
Newport Laboratories for viral isolation and characterization as part of
routine diagnostic testing. Samples originated from various commercial
swine production sites in North Carolina in 2010 and 2011 (designated by
virus identifier prefix; for example, isolate 10-0036-2 was isolated in
2010). Virus isolation was performed on swine testicle (ST) cells grown in
Dulbecco’s modified Eagle’s medium (DMEM) containing 5% fetal bovine serum (FBS) at 37°C with 5% CO2. For viral propagation, fetal bovine
serum was omitted from the DMEM. 293T and MDCK cells were propagated in DMEM containing 10% fetal bovine serum.
Genetic analysis. RNA was harvested from infected cell culture harvest fluids by use of a 5⫻ MagMax-96 viral isolation kit (Life Technologies). Complete viral genomes were amplified using a previously described multisegment reverse transcription-PCR method (33). Viral
cDNA libraries were prepared using an NEB Next Fast DNA fragmentation and library prep set 4 kit according to the manufacturer’s instructions
(New England BioLabs), with the exception that the kit adaptors were
replaced with bar-coded adaptors (Ion Xpress Barcode Adaptor 1-16 kit;
Life Technologies). DNA sequencing templates were prepared using an
Ion Xpress template kit, version 2.0 (Life Technologies), and sequenced
using an Ion Torrent personal genome machine (Life Technologies).
Contigs were assembled using SeqMan NGen software (DNAStar). Contigs encoding full-length HA were identified by BLAST analysis.
Full-length HA DNA sequences were aligned using the ClustalW method.
Phylogenetic analyses were performed using MEGA 5.0 via the neighborjoining method, and tree topology was verified by use of 1,000 bootstrap
replicates (26).
Serological assays. Antibody cross-reactivity was determined using a
panel of reference antisera in hemagglutination inhibition (HI) and highthroughput serum neutralization (HTSN) assays (11). Antiserum against
an isolate from each of the five subclusters of the ␦ cluster was generated in
pigs and normalized to a homologous HI titer of 1,280 as previously
described (11). Antiserum was also generated against the ST cell line as a
control. All sera were heat inactivated at 56°C for 30 min prior to use.
HI assays were performed following standard procedures (7). In brief,
sera were treated with a receptor-destroying enzyme for 24 h at 37°C and
then adsorbed with a 20% suspension of turkey erythrocytes in phosphate-buffered saline (PBS) for 30 min at room temperature. Virus suspensions containing 4 to 8 HA units of virus were incubated for 1 h with
serial 2-fold dilutions of antiserum, and the HI titer was determined as the
reciprocal of the highest dilution that showed complete inhibition of
hemagglutination using 0.5% washed turkey erythrocytes. Antigenic cartography was performed using the program AntigenMap (http://sysbio
.cvm.msstate.edu/AntigenMap), which utilizes matrix completion multidimensional scaling (MC-MDS) to map HI titers in two dimensions (5).
Serum neutralization assays were performed as previously described,
with slight modifications (32). Two-fold serial dilutions in PBS, from 1:4
to 1:32,768, were performed on the sera. Next, 100 l of 40 to 200 median
tissue culture infective doses (TCID50)/100 l of virus was added to each
serum dilution and incubated for 1 h at 37°C in 5% CO2. The serum-virus
mixture was next transferred to a confluent monolayer of ST cells and
incubated at 37°C in 5% CO2 for 4 days. Viral neutralization was assessed
by a lack of cytopathic effects in each well by microscopy. Back titrations
were performed on ST cells to confirm a virus concentration of 40 to 200
TCID50/100 l.
The HTSN assay was performed as previously described (11, 12).
Briefly, antisera were diluted 1:800 in DMEM, combined with 1,000 median TCID50 of virus, and incubated at 37°C for 1 h. The virus-antiserum
mixture was next transferred to a confluent monolayer of ST cells and
incubated for 4 days at 37°C. Nonneutralized virus was assayed by incubating cell culture supernatants for 2 h with methylumbelliferyl-N-acetylneuraminic acid and measuring fluorescence with excitation and emission filters of 355 and 460 nm, respectively. The mean of duplicate
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FIG 1 Genotypes of viruses created using reverse genetics. Blue bars represent
genes from A/swine/North Carolina/3793/08, yellow bars represent genes
from field isolate 10-0036-2, and the green bar represents a gene from field
isolate 11-0854-1.

fluorescence values was used to calculate the serum neutralization ratio, as
follows: neutralization ratio ⫽ (sample value ⫺ virus-only control value)/
(no-virus control value ⫺ virus-only control value). A serum neutralization ratio of ⬎0.31 was previously determined to indicate positivity for
neutralization (12).
Reverse genetics. A triple-reassortant internal gene cassette (TRIG)
swine influenza virus (A/swine/North Carolina/3793/08 [H1N1]) was
used as the template to create a TRIG swine influenza virus reverse genetics system. All eight segments were PCR amplified, digested with BsmBI,
and ligated into similarly digested pHW2000 as previously described (15).
Plasmids bearing an insert were identified by restriction digestion and
sequenced to verify identity with A/swine/North Carolina/3793/08. The
HA and NA genes from neutralization-sensitive isolate 10-0036-2 were
also cloned into pHW2000 and transfected along with plasmids bearing
polymerase basic 2 (PB2), polymerase basic 1 (PB1), polymerase acid
(PA), nucleoprotein (NP), matrix (M), and nonstructural (NS) genes derived from A/swine/North Carolina/3793/08 to produce a reverse genetics-derived isolate (RG 10-0036-2) (Fig. 1). Additionally, the HA gene
from neutralization-resistant isolate 11-0854-1 was cloned and transfected along with plasmids containing the NA gene from isolate 10-0036-2
and the PB2, PB1, PA, NP, M, and NS genes from A/swine/North Carolina/3793/08 to create RG 11-0854-1. Site-directed mutagenesis was performed on plasmids containing HA genes from isolates 10-0036-2 and
11-0854-1 to create mutants RG 10-0036-2 T144N and RG 11-0854-1
N144T, respectively, using a QuikChange II site-directed mutagenesis kit
(Agilent Technologies).
Rescue of recombinant viruses was performed as previously described
(16). In brief, 293T and MDCK cells were cocultured in Opti-MEM I
containing 5% FBS in 6-well plates containing approximately 1 ⫻ 106 cells
each of 293T and MDCK cells approximately 18 h prior to transfection.
One hundred nanograms of each of the eight plasmids was pooled in 100
l of Opti-MEM I, combined with 100 l Opti-MEM containing 3 l
Lipofectamine (Invitrogen), and incubated at room temperature for 15
min before being diluted to 1 ml with Opti-MEM I and transferred to a
single well of the 6-well plate. Plates were incubated at 37°C with 5% CO2
for 6 h before the transfection mixture was replaced with Opti-MEM I. At
24 h posttransfection, 1.5 ml of each mixture was transferred to a 6-well
plate of confluent MDCK cells, and 1.5 ml of DMEM containing 1 g/ml
of tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin was added. Viruses were harvested on day 5 postinfection, and their
titers were determined by HA assay. The HA genes of rescued viruses were
sequenced to verify the correct sequence.
Hemagglutinin modeling. Homologs of neutralization-sensitive isolate 10-0036-2 with either T or N at position 144 were searched against the
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TABLE 1 Summary of HTSN ratios of ␦-subcluster E field isolates
tested against ␦-subcluster antiseraa

TABLE 2 HI antibody titers of ␦-subcluster E isolates against ␦subcluster antiseraa

HTSN ratio with indicated antiserum
Viral
isolate

N siteb

␦-A

␦-B

␦-C

␦-D

10-2858-1
11-0667-1
11-0669-1
11-0854-1
11-1553-1
10-1287-1
10-3025-1
10-3215-1
11-0376-1
11-1035-1

144
144
144
144
144
142
142
142
137
142

0.08
0.12
0.11
0.05
0.06
0.06
0.05
0.05
0.09
0.13

0.02
0.07
0.07
0.02
0.03
0.02
0.02
0.01
0.00
0.04

0.01
0.03
0.04
0.01
0.02
0.98
1.00
0.98
0.96
0.97

0.02
0.05
0.07
0.00
0.02
0.98
1.00
0.98
0.96
0.97

a
b

HI antibody titer against indicated antiserum

␦-E

ST cell
antiserum

Viral
isolate

N siteb

␦-A

␦-B

␦-C

␦-D

␦-E

ST cell
antiserum

0.00
0.01
0.03
0.04
0.01
0.99
1.00
0.99
0.97
0.98

0.03
0.06
0.04
0.00
0.01
0.02
0.00
0.00
0.01
0.02

10-2858-1
11-0667-1
11-0669-1
11-0854-1
11-1553-1
10-1287-1
10-3025-1
10-3215-1
11-0376-1
11-1035-1

144
144
144
144
144
142
142
142
137
142

0
0
0
0
0
0
0
0
0
0

17
0
10
20
20
0
0
10
0
0

0
0
0
0
0
2,560
2,560
1,707
2,133
2,560

0
0
0
0
0
640
640
640
160
640

80
0
80
80
80
853
1,067
1,067
320
1,280

0
0
0
0
0
0
0
0
0
0

Positive ratios are shown in bold. Results are means for duplicate analyses.
Amino acid position of N-linked glycosylation.

Protein Data Bank (PDB) structure database by using BLASTP with default parameters (2). The structures of HA proteins with T144 or N144 in
complex with neutralizing antibody were built using Modeller, with PDB
structure 3SM5 as the template (10-0036-2 and 3SM5 sequence identity
was 92%) (20). Homologs with glycosylation sites at N142 or N144 were
glycosylated artificially with a complex N-glycan (Glycom-DB accession
no. 8793) by using Glyprot (3). The preferred orientation of the attached
N-glycan relative to the glycosylation site was chosen using default parameters, based on knowledge of the orientation preference of glycans in
known glycoproteins (3). We superimposed and replaced the HA in structure 3SM5 with our modeled HA by using Pymol.
Nucleotide sequence accession numbers. HA gene sequences were
deposited in GenBank under accession numbers JQ638655 to JQ638665.

RESULTS

Genetic analysis identified a conserved N144 mutation present
only in nonreactive viruses in HTSN and HI assays. During our
regular surveillance of genetic diversity and antigenic variation of
swine influenza virus HA from 2010 to 2011, using an HTSN assay
incorporating a panel of reference antisera generated against representative viruses of contemporary circulating influenza viruses,
we found that neutralization-resistant viruses accounted for approximately 20% of virus isolates studied. In order to understand
the molecular basis of antigenic variation, we randomly selected
five neutralization-sensitive isolates and five neutralization-resistant isolates for further genetic and antigenic analysis.
Consistent with our previous observation (data not shown),
isolates 10-1287-1, 10-3025-1, 10-3215-1, 11-1035-1, and 110376-1 were all neutralized by antisera generated against ␦-subclusters C, D, and E (Table 1). Similarly, the same isolates had high
HI titers with the same antisera (mean titer ⫽ 1,255) (Table 2). In
contrast, isolates 10-2858-1, 11-0667-1, 11-0669-1, 11-0854-1,
and 11-1553-1 were all negative in the HTSN assay and had low HI
titers, against ␦-subclusters B and E only (mean titers ⫽ 13 and 64,
respectively).
Next, we sequenced the full-length HA genes of all 10 viruses.
The results showed that these viruses share ⬎97% amino acid
identity and all belong to ␦-subcluster E (Fig. 2). Subsequent analysis of predicted N-linked glycosylation sites (N-X-S/T) found
conserved sites at N28, N40, N104, N176, N303, N497, and N556
among these viruses (data not shown). Interestingly, we noted
that five neutralization-resistant viruses (10-2858-1, 11-0667-1,
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a
b

Means for triplicate analyses are shown.
Amino acid position of N-linked glycosylation site.

11-0669-1, 11-0854-1, and 11-1553-1) all possessed an eighth additional glycosylation site, at N144 (Fig. 3). In contrast, four viruses (10-1287-1, 10-3025-1, 10-3215-1, and 11-1035-1) had the
eighth predicted glycosylation site at N142, and one virus (110376-1) had the remaining glycosylation site at N137. The last five
viruses were neutralized by reference antisera in the HTSN assay.
Variation in potential N-linked glycosylation at N142 and N144
has been observed previously in human influenza virus HA proteins (24, 31). Thus, our results appear to suggest a potential link
between glycosylation pattern alteration centering at N142/N137
or N144 and susceptibility of viruses to neutralization.
Migration of N-linked glycosylation site from N142 to N144
is responsible for discriminating viruses into neutralizationsensitive and neutralization-resistant groups. To elucidate the
genetic basis for the observed antigenic variation, two approaches

FIG 2 Phylogenetic analysis of the hemagglutinin proteins of the swine influenza virus ␦-cluster isolates used in this study.
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FIG 3 Hemagglutinin amino acid sequences for positions 122 to 162. Potential N-linked glycosylation sites are shaded in gray. The amino acids located in the
Sa epitope are P141 and N142. Viruses with the prefix “RG” were engineered using reverse genetics.

were pursued in this study. One approach was to develop a reverse
genetics system that allowed for rescue of representative viruses,
while the other approach was to employ site-specific mutagenesis
to study how the presence or absence of N144 impacts viral susceptibility to neutralization.
A TRIG swine influenza virus reverse genetics system was created using H1N1 A/swine/North Carolina/3793/08. We selected
neutralization-sensitive virus 10-0036-2, containing N142 and
T144, and neutralization-resistant virus 11-0854-1, containing
N142 and N144, as representative strains in our study. HA and NA
segments derived from isolate 10-0036-2 were combined with a
TRIG swine influenza virus backbone consisting of the PB2, PB1,
PA, NP, M, and NS genes to rescue the reverse genetics-derived
virus RG 10-0036-2 (Fig. 1). RG 11-0854-1 virus was recovered
from 293T and MDCK cells transfected with the HA segment
derived from isolate 11-0854-1 together with the NA segment of
isolate 10-0036-2 in combination with the TRIG swine influenza
virus backbone.
A replacement of threonine (T) at HA position 144 with asparagine (N) was made in the context of the neutralization-sensitive
isolate RG 10-0036-2, and the resultant virus was designated RG
10-0036-2 T144N. Asparagine substitution at position 144 abrogates N142-associated N-linked glycosylation but provides a new
glycosylation site, resembling the case in the neutralization-resistant strains. Conversely, the asparagine at position 144 was replaced by threonine in neutralization-resistant isolate RG 110854-1 without altering any other amino acids, including N142.
The derived virus, designated RG 11-0854-1 N144T, mimics neutralization-sensitive viruses. We did not perform site-directed
mutagenesis on the N-linked glycosylation site at N137, as observed for 11-0376-1, because a search of our influenza virus HA
sequence database identified only three instances (⬍1%) of N137.
Next, we characterized these mutant viruses in parallel with
their parental strains in serological assays for susceptibility to neutralization or inhibition by the reference antisera. Reverse genetics-derived viruses were serologically similar to their corresponding parent viruses (Tables 3, 4, and 5). RG 10-0036-2 was
neutralized by ␦-subcluster C, D, and E antisera in the HTSN assay
(Table 3). Similarly, HI titers for these antisera were 1,280, 267,
and 640, respectively, against RG 10-0036-2 (Table 4). RG 100036-2 has a predicted glycosylation site at N142, and 10-0036-2 is
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the isolate used to generate ␦-subcluster E antisera. In contrast,
RG 10-0036-2 T144N, with the disappearance of N142 glycosylation but the appearance of potential N144 glycosylation, was not
neutralized by any ␦-subcluster antisera in the HTSN assay and
had HI titers of 13 and 40 for antisera generated against subclusters B and E, respectively. This result was further supported in the
gain-of-function experiment described below. RG 11-0854-1,
which is similar to RG 10-0036-2 T144N in that it has a predicted
glycosylation site at N144 but not at N142, was also not neutralized by any ␦-subcluster antiserum and had similar HI titers (␦-B
antibody titer of 20 and ␦-E antibody titer of 80). Significantly,
however, the N144T mutation and predicted glycosylation site at
N142 rendered RG 11-0854-1 susceptible to antibody-mediated
neutralization in HTSN assays and to inhibition in HI assays. Additionally, genetically engineered viruses and their parents were
assayed by traditional serum neutralization assays. Regression
analysis of HI and SN titers found a strong correlation (R2 ⫽ 0.86).
Antisera generated from ␦-C, ␦-D, and ␦-E viruses had SN titers in
excess of 10,000 for viruses with predicted glycosylation at N142
(10-0036-2, RG 10-0036-2, and RG 11-0854-1 N144T) (Table 5).
In contrast, the same antisera had a ⬎8-fold drop in titer for
viruses with predicted glycosylation at N144 (RG 10-0036-2
T144N, 11-0854-1, and RG 11-0854-1). While neutralizing anti-

TABLE 3 HTSN ratios of parent and reverse genetics-derived viruses
and mutantsa
HTSN ratio with indicated
antiserum
Virus

N siteb

␦-A

␦-B

␦-C

␦-D

␦-E

ST cell
antiserum

10-0036-2
RG 10-0036-2
RG 10-0036-2
T144N
11-0854-1
RG 11-0854-1
RG 11-0854-1
N144T

142
142
144

0.07
0.03
0.04

0.03
0.01
0.02

0.99
1.00
0.01

0.99
1.00
0.01

1.00
1.00
0.01

0.01
0.00
0.02

144
144
142

0.05
0.04
0.07

0.02
0.00
0.01

0.01
0.01
0.98

0.00
0.00
0.98

0.04
0.11
0.98

0.00
0.00
0.00

a

Positive ratios are shown in bold. Means for duplicate analyses are shown. “RG”
denotes strains derived by reverse genetics.
Amino acid position of N-linked glycosylation site.

b
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TABLE 4 HI antibody titers of parent and reverse genetics-derived
viruses and mutantsa

TABLE 5 SN antibody titers of parent and reverse genetics-derived
viruses and mutantsa

HI antibody titer against indicated antiserum
Virus

N siteb

␦-A

␦-B

␦-C

␦-D

␦-E

ST cell
antiserum

10-0036-2
RG 10-0036-2
RG 10-0036-2
T144N
11-0854-1
RG 11-0854-1
RG 11-0854-1
N144T

142
142
144

0
0
0

0
0
13

1,280
2,560
0

267
1,707
0

640
1,067
40

0
0
0

144
144
142

0
0
10

20
17
10

0
0
2,560

0
0
320

80
80
1,280

0
0
0

SN antibody titer against antiserum
Virus

N siteb

␦-A

␦-B

␦-C

␦-D

␦-E

ST cell
serum

10-0036-2
RG 10-0036-2
RG 10-0036-2
T144N
11-0854-1
RG 11-0854-1
RG 11-0854-1
N144T

142
142
144

362
362
91

362
362
181

23,170
16,384
91

11,585
11,585
45

23,170
23,170
724

11
3
23

144
144
142

23
45
181

362
181
362

181
91
23,170

23
23
23,170

2,896
2,896
23,170

11
11
0

a

Means for triplicate analyses are shown. “RG” denotes strains derived by reverse
genetics.
b
Amino acid position of N-linked glycosylation site.

a

bodies were measurable for all reactions, the trends in serum neutralizing titers closely matched the titers measured by the HI assay,
i.e., high-titer antibodies present in ␦-C, ␦-D, and ␦-E antisera
recognized viruses with predicted glycosylation at N142, and migration of this glycosylation site to N144 resulted in a substantial
loss in antibody binding. Thus, the results of our experiments
demonstrate that a shift of the predicted N-linked glycosylation
site at N142 to N144 is responsible for some swine influenza viruses escaping neutralization by antibody.
Antigenic cartography was performed to visualize the HI data.
Neutralization-resistant viruses clustered within 1.5 log2 of each
other (Fig. 4, red dots). A similar small distribution was found for
neutralization-sensitive viruses (green dots). The neutralizationresistant and -sensitive clusters were separated by 2 to 3 log2. Reverse genetics-created viruses clustered within 1 log2 of their wildtype parent strains, and mutation of the potential glycosylation
site from N142 to N144, or vice versa, led to a 2- to 3-log2 change
in cartographic position.
Structural modeling of neutralizing antibody in complex
with hemagglutinin further suggests a role for N144 in mediating viral evasion of antibody recognition. To provide a structural
basis for N144-directed viral evasion of neutralization and to explore a new avenue for designing a broad-spectrum antibody response, we conducted structural modeling of neutralizing antibody in complex with swine influenza virus HA antigen
containing a predicted glycosylation site at N142 or N144. The
structure of the H1 ectodomain and associated neutralizing antibody (PDB accession no. 3SM5) was used as a template to perform
homology modeling, while a complex glycan was artificially superimposed on either the N142 or N144 site. As demonstrated in
Fig. 5, the glycan at N142 extends away from the contact between
the HA head domain and the antibody, thereby exhibiting no
interference with the interaction between antibody and viruses
observed in the neutralization of viruses such as 10-0036-2 or RG
11-0854-1 N144T. In marked contrast, the complex glycan at
N144 forms strong steric clashes with residues of the antibody
heavy chain (Fig. 6), which may prevent the binding of the antibody heavy chain to the HA head domain for viruses that result in
nonneutralizing phenotypes, such as 11-0854-1 or RG 10-0036-2
T144N. Our model also shows that the distance between residue
E102 of the antibody heavy chain and the first and second glycans
of N144 (Fig. 6) is shorter than the van der Waals radius of two

atoms (⬃2.8 Å). Such a short distance might lead to steric clash,
and as a result, addition of one or two glycans to HA N144 will
affect HA-antibody interaction. Together with the above serology
data, this strongly suggests that the presence of an asparagine at
HA position 144 and the associated potential N-linked glycosylation may abolish antibody binding in a subset of swine influenza
viruses, probably by inducing a steric hindrance effect.
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Means for duplicate analyses are shown. “RG” denotes strains derived by reverse
genetics.
b
Amino acid position of N-linked glycosylation site.

DISCUSSION

Killed viral vaccines are commonly used in the United States to
control swine influenza virus. Most vaccines are multivalent, containing genetically and antigenically distinct viruses to elicit
broadly cross-reactive antibodies. Sequencing of the hemagglutinin gene is a standard practice for assessing genetic relationships
and selection of vaccine strains. Variation in hemagglutinin Nlinked glycosylation is a known mechanism employed by influenza virus to evade host immune responses; however, analysis of
glycosylation variability is not routinely performed for swine influenza viruses in the swine industry. Additionally, the effects of
glycosylation pattern changes (in both the number of sites and
location) on antigenicity are not well understood for swine influenza virus.
Routine antigenic analysis in our laboratory, using swine influenza virus isolates from clinical submissions, found evidence for
considerable antigenic drift, with 20% of isolates not being neutralized by a broad panel of antisera generated against all genetic
clusters of influenza virus circulating in the United States. Genetic
analysis of the HA genes of these isolates found that nearly all are
within the ␦ cluster, a seasonal human influenza virus lineage (28).
Hemagglutinin sequence analysis found a conserved T144N mutation (at the predicted glycosylation site at N144) present in all
isolates that were not neutralized in the HTSN assay. Analysis of
the glycosylation patterns of seasonal human influenza viruses
found that a majority of viruses from 1940 to 1985 were glycosylated at N144 (24). Conversely, nearly all seasonal human influenza viruses from 1986 to the present were glycosylated at N142.
Swine influenza viruses containing human seasonal influenza virus HA genes were first identified in 2003, and accordingly, N142
is most common in swine influenza virus isolates with human
lineage HA (17).
In this study, we confirmed that viruses containing N144,
which is located in a consensus glycosylation sequence motif, are
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FIG 4 Antigenic cartograph of influenza viruses, constructed by AntigenMap (http://sysbio.cvm.msstate.edu/AntigenMap) using hemagglutination inhibition
titers. Pink, ␦-cluster reference antisera; green, neutralization-sensitive influenza virus isolates; red, neutralization-resistant influenza virus isolates; blue, reverse
genetics-derived isolate 11-0854 (RG 11-0854-1) and N144T mutant; yellow, reverse genetics-derived isolate 10-0036-2 (RG 10-0036-2) and T144N mutant.

not neutralized by antisera generated against genetically similar
viruses exhibiting a predicted glycosylation site at N142. Four field
isolates with N142 and one with N137 were all neutralized by
well-matched antisera in HTSN assays and effectively inhibited in

FIG 5 Structural modeling of neutralizing antibody in complex with swine influenza virus HA antigen containing a predicted glycosylation site at N142. The structure of the H1 ectodomain and associated neutralizing antibody (PDB accession
no. 3SM5) was used as a template to perform homology modeling, while a complex glycan was artificially superimposed on the N142 site. Orange, HA; green,
antibody heavy chain; cyan, antibody light chain; magenta, glycans.
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HI and SN assays. Conversely, viruses with the T144N change
were not neutralized in the HTSN assay and exhibited much less
inhibition in HI and SN assays. N142 is located in the well-characterized Sa epitope, while N144 is immediately adjacent. The Sa
epitope is located on the top part of the HA globular head, and
mutations in this region have previously been shown to have a
pronounced effect on viral antigenicity (6, 23, 31). To eliminate
the possibility of other genetic differences, viruses possessing glycosylation consensus sequences at N142 or N144 were created by
reverse genetics and subsequently mutated to migrate the glycosylation consensus sequence to N144 or N142, respectively. Crossreaction of the engineered viruses was consistent with observations from field isolates with respect to the glycosylation sequence
located at either N142 or N144. Antigenic cartography also illustrated that the neutralization-sensitive and -resistant phenotypes
were determined by differential glycosylation at N142 and N144.
In this study, we also attempted to address whether the N142
and N144 mutations altered the glycosylation patterns of the HA
proteins of both viruses. Examination of purified virions from
both viruses by SDS-PAGE and Western blotting revealed a shift
in mobility of HA proteins when peptide N-glycosidase F-treated
and nontreated samples were compared directly, indicating that
N142- and N144-carrying HA proteins are modified by N-linked
glycans (data not shown). A previous study convincingly demonstrated N142-linked glycosylation (8). No visible differences in
HA mobility were observed for viruses bearing N-linked glycosylation sites at N142 or N144. This result was expected, as the numbers of potential glycosylation sites in HA proteins containing
N142 or N144 are equivalent. Alternatively, it could be suggested
that the low-resolution SDS-PAGE/Western blotting assay using
polyclonal antisera may not detect any quantitative difference in
glycosylation patterns that may occur in HA proteins with an

Clinical and Vaccine Immunology

Migration of Inﬂuenza Virus HA Glycosylation Site

FIG 6 Structural modeling of neutralizing antibody in complex with swine
influenza virus HA antigen containing a predicted glycosylation site at N144.
Panels B and C are magnified images of the antigen-antibody contact surface
shown in panel A, with different magnifications focusing on different regions.
The antibody-binding pocket on HA is shown using a surface diagram, while
antibody and other regions of HA are shown as ribbon diagrams. Orange, HA;
green, antibody heavy chain; cyan, antibody light chain. N137, N142, and
N144 are colored marine (B), while glycans on N144 are colored magenta (C).
In panel C, a residue on the antibody heavy chain that is close to N144 of HA is
colored yellow, and the distances from the closest atoms to this residue of the
heavy chain and residue N144 are shown (the atoms are antibody heavy chain
E102 OE1 and HA N144 ND2). All oxygen atoms and nitrogen atoms shown
are colored red and blue, respectively.

N142 or N144 mutation. In this regard, a high-resolution mass
spectrometry approach will be pursued in our future work.
To elucidate the structural basis for the lack of cross-reactivity
of antibodies generated against viruses with N142 to those with
N144, models of hemagglutinin in complex with neutralizing antibody were developed. The complex glycan attached to N144 is
projected from the hemagglutinin head domain, which may sterically hinder binding of the antibody heavy chain. Conversely,
N142-carrying viruses had complex glycans extended away from
the antigen-antibody contact interface, which may not interfere
with antibody binding to HA protein. Additionally, a recent genetic analysis of influenza virus glycosylation site migrations suggested that glycosylation at N142 better protects the antigenic Sa
site, while glycosylation at N144 is more effective at shielding the
antigenic Sb site (25). Thus, the modeling data appear to explain
the observed results of our HTSN, HI, and SN assays, showing that
antibody is sterically hindered from binding to the head domain of
HA for viruses with N144-associated glycans, as well as supporting
other predictions based on genetic and structural studies.
Genetic analysis of ␦-cluster hemagglutinin sequences in the
Newport Laboratories swine influenza virus database found a low
prevalence of viruses with N144 prior to 2009 (3.6%). From 2009
to 2011, viruses with N144 represented 18.5% of ␦-cluster isolates,
and viruses with N144 were identified in each of the five ␦ subclusters. It can be postulated that these viruses are neutralization resistant, though further experiments are needed to prove this hypothesis. Phylogenetic analysis shows a close relationship between
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neutralization-resistant and neutralization-sensitive viruses, suggesting that the neutralization-resistant viruses evolved from the
neutralization-sensitive ␦-cluster viruses circulating in swine
since 2003, possibly due to immune selection pressure. Given that
swine influenza viruses within the ␦ cluster contain an HA gene
derived from human seasonal influenza virus and that viruses with
N-linked glycosylation at position 144 have not circulated in humans since 1985, individuals born thereafter may be more vulnerable to zoonotic transmission of these viruses, as previous work
has shown no cross-protection between H1 vaccine strains produced prior to 1986 and vaccines produced in subsequent years
(13). Importantly, vaccines for swine influenza virus may require
multiple strains of ␦-cluster isolates representing glycosylation
variants. This work also highlights the limitations of genetic analysis alone, illustrating the need for coupled antigenic surveillance
of influenza virus.
Finally, our observation that relocation of potential N-linked
glycosylation sites protects swine influenza virus from rapid neutralization by antibodies is interesting and novel. It suggests a role
for immune selection in influenza virus in swine. While this study
clearly demonstrates the effect of glycosylation on in vitro antigenicity, little is known about the role of glycosylation on in vivo
immunogenicity, which will be a focus of future investigations.
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